StockIQpro
NASDAQ:TYRA

Tyra Biosciences, Inc.

Track all markets on TradingView
Track all markets on TradingView

Tyra Biosciences, Inc. reported net income of −$119.9M in fiscal 2025. Free cash flow was −$95.3M, and the diluted share count rose 4.2%.Summary generated from Tyra Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−39.8%
Debt / equityn/a
Free cash flow−$95.3M
FCF marginn/a
Share count change+4.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−26−59−80−104−133
Net income−26−55−69−86−120
Free cash flow−24−51−51−70−95

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations